Brief Report: Childhood‐Onset Systemic Necrotizing Vasculitides: Long‐Term Data From the French Vasculitis Study Group Registry

To describe the initial features and long‐term outcomes of childhood‐onset small vessel and medium vessel systemic necrotizing vasculitides (SNVs), including antineutrophil cytoplasmic antibody–associated vasculitides (AAVs) and polyarteritis nodosa (PAN).

[1]  M. Matucci-Cerinic,et al.  Clinical overview and outcome in a cohort of children with polyarteritis nodosa. , 2014, Clinical and experimental rheumatology.

[2]  N. Klein,et al.  Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. , 2013, Arthritis and rheumatism.

[3]  S. Spalding,et al.  Childhood-onset Eosinophilic Granulomatosis with Polyangiitis (formerly Churg-Strauss Syndrome): A Contemporary Single-center Cohort , 2013, The Journal of Rheumatology.

[4]  S. Özen,et al.  Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS) , 2012, Annals of the rheumatic diseases.

[5]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[6]  A. Bakkaloğlu,et al.  EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria , 2010, Annals of the rheumatic diseases.

[7]  A. Reiff,et al.  Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. , 2009, Arthritis and rheumatism.

[8]  J. Zwerina,et al.  Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. , 2009, Seminars in arthritis and rheumatism.

[9]  R. Schneider,et al.  Clinical features and outcome of pediatric Wegener's granulomatosis. , 2007, Arthritis and rheumatism.

[10]  H. Raspe,et al.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis , 2006, Annals of the rheumatic diseases.

[11]  W. Kuis,et al.  Juvenile polyarteritis: results of a multicenter survey of 110 children. , 2004, The Journal of pediatrics.

[12]  V. Shah,et al.  Clinical features in 17 paediatric patients with Wegener granulomatosis , 2002, Pediatric Nephrology.

[13]  S. Ozen,et al.  The significance of antineutrophil cytoplasmic antibody in microscopic polyangitis and classic polyarteritis nodosa , 2001, Archives of disease in childhood.

[14]  M. Hattori,et al.  Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. , 2001, Journal of the American Society of Nephrology : JASN.

[15]  B. Malmer,et al.  Wegener granulomatosis in children and young adults. A case study of ten patients. , 2000, Pediatric nephrology.

[16]  C. Gordon,et al.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.

[17]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[18]  Guy Hoffman,et al.  Wegener granulomatosis in children and adolescents: clinical presentation and outcome. , 1993, The Journal of pediatrics.

[19]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. , 2010, Arthritis and rheumatism.